Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Central Line Sepsis Clear all
Terminated Not applicable Interventional Results available

The Pristine Post-Market Study

NCT05228132
View directory record Official record
Conditions
Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure, Central Venous Catheter Related Bloodstream Infection, End Stage Renal Disease
Interventions
Pristine™ Long-Term Hemodialysis Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
6
States / cities
Dothan, Alabama • New Haven, Connecticut • Shreveport, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Jul 21, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections

NCT00130221
View directory record Official record
Conditions
Nosocomial Infection, Bacteremia, Sepsis, Pneumonia, Urinary Tract Infection, Clostridium Infection
Interventions
2% chlorhexidine gluconate impregnated cloth, Daily bathing with Bar soap
Drug · Other
Lead sponsor
Cook County Health
Government
Eligibility
16 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 21, 2026, 11:09 PM EDT
Completed Not applicable Interventional

The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants

NCT00964093
View directory record Official record
Conditions
Central Line Bloodstream Infections
Interventions
Silver Alginate
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
1 Day to 3 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 21, 2026, 11:09 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections

NCT00027248
View directory record Official record
Conditions
Sepsis, Bacteremia, Fungemia
Interventions
MBI 226
Drug
Lead sponsor
BioWest Therapeutics Inc
Industry
Eligibility
16 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Lake Bluff, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2005 · Synced Jul 21, 2026, 11:09 PM EDT
Not yet recruiting Not applicable Interventional

CVCs Versus Midline Catheters

NCT06884176
View directory record Official record
Conditions
Central Venous Catheter, Midline Catheter, Complication of Catheter
Interventions
Ultrasound Guided Central Venous Catheter, Ultrasound Guided Midline Catheter
Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 21, 2026, 11:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Implementation Program to Improve CHG Bathing Compliance

NCT03898115
View directory record Official record
Conditions
Central Line-associated Bloodstream Infection (CLABSI)
Interventions
CHG Education
Behavioral
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Jul 21, 2026, 11:09 PM EDT
Completed Phase 2 Interventional

Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI)

NCT01539343
View directory record Official record
Conditions
Infection
Interventions
Antimicrobial Solution
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2016 · Synced Jul 21, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection

NCT03672006
View directory record Official record
Conditions
Central Venous Catheter Thrombosis, Central Venous Catheter Associated Bloodstream Infection
Interventions
alteplase (recombinant t-PA), Heparin
Biological · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Jul 21, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

NCT01817075
View directory record Official record
Conditions
Bacterial Infection, Benign Neoplasm, Malignant Neoplasm, Methicillin-Resistant Staphylococcus Aureus Infection, Myeloid Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions
Chlorhexidine Gluconate Skin Cleanser, Laboratory Biomarker Analysis, Mild Soap Skin Cleanser, Questionnaire Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Months to 21 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
53
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jul 21, 2026, 11:09 PM EDT
Terminated Not applicable Interventional

Efficacy and Safety of Ethanol Lock Therapy for the Prevention of Central Line-associated Bloodstream Infections

NCT02890875
View directory record Official record
Conditions
Catheter-Related Infections
Interventions
Ethanol lock, Heparin lock
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Jul 21, 2026, 11:09 PM EDT
Terminated Not applicable Interventional Results available

Innovative Central Line Securement Device in the Pediatric Population

NCT04522778
View directory record Official record
Conditions
Central Line Complication, Central Line Infection, Central Line-Associated Infection, Central Line Sepsis, Short Gut Syndrome, Quality of Life, Pediatric Disorder
Interventions
Wearable Central Line Securement Device (Vest), Traditional Securement Dressing
Device · Other
Lead sponsor
Ryan St. Pierre-Hetz
Other
Eligibility
0 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Jul 21, 2026, 11:09 PM EDT
Terminated Phase 3 Interventional Results available

Ethanol Locks for the Treatment of Central Venous Line Infections

NCT00680459
View directory record Official record
Conditions
Bloodstream Infection
Interventions
70% ethanol, heparin flush solution
Drug
Lead sponsor
Baystate Medical Center
Other
Eligibility
6 Months to 23 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Jul 21, 2026, 11:09 PM EDT
Suspended Not applicable Interventional

Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients

NCT04559334
View directory record Official record
Conditions
Central Line Complication, Central Line-associated Bloodstream Infection (CLABSI)
Interventions
Tetrasodium EDTA Catheter Lock Solution
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Months to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 21, 2026, 11:09 PM EDT
Recruiting Phase 4 Interventional

Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age

NCT06714864
View directory record Official record
Conditions
Catheter-Related Infections
Interventions
(taurolidine and heparin) catheter lock solution, Standard of Care
Drug
Lead sponsor
CorMedix
Industry
Eligibility
Up to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 21, 2026, 11:09 PM EDT
Completed Not applicable Interventional Results available

Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT

NCT02575079
View directory record Official record
Conditions
Central Line Associated Bloodstream Infections (CLABSI), Bone Marrow Transplant
Interventions
Parafilm
Device
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Jul 21, 2026, 11:09 PM EDT
Not yet recruiting No phase listed Observational

Duke Virtual IntEgrated Workflow

NCT07406074
View directory record Official record
Conditions
Falls Injury, Readmission Rates, CLABSI - Central Line Associated Bloodstream Infection, Catheter Associated Urinary Tract Infection, Hospital Acquired Pressure Injury, Venous Thromboembolism (VTE), Nurses, Satisfaction, Patient, Length of Stay
Interventions
Co-Care
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 21, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

NCT02651428
View directory record Official record
Conditions
Kidney Failure, Chronic, Catheter-Related Infections
Interventions
Neutrolin, Heparin
Drug
Lead sponsor
CorMedix
Industry
Eligibility
18 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Riverside, California • San Dimas, California • Miami Gardens, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Jul 21, 2026, 11:09 PM EDT
Available No phase listed Expanded access

Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

NCT04513821
View directory record Official record
Conditions
Catheter-Related Infections
Interventions
Mino-Lok Therapy (MLT)
Drug
Lead sponsor
Leonard-Meron Biosciences, Inc.
Industry
Eligibility
12 Years and older
U.S. locations
27
States / cities
Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Jul 21, 2026, 11:09 PM EDT
Not listed Not applicable Interventional

Umbilical Cord Care for the Prevention of Colonization

NCT01893060
View directory record Official record
Conditions
Line Insertion Site, Central Line-associated Bloodstream Infection (CLABSI)
Interventions
Povidone-Iodine, Chlorhexidine gluconate, Pluronic Cream, control
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
Up to 7 Days
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Jul 21, 2026, 11:09 PM EDT
Not listed Phase 1Phase 2 Interventional

Evaluating Central Line Hub Contamination Using a Novel Capping Device

NCT01301300
View directory record Official record
Conditions
Catheter-related Bloodstream Infection Due to Central Venous Catheter
Interventions
Disinfecting Cap
Device
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Evanston, Illinois • Glenview, Illinois • Highland Park, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2011 · Synced Jul 21, 2026, 11:09 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition

NCT02227329
View directory record Official record
Conditions
Catheter-related Bloodstream Infection (CRBSI) Nos, Bloodstream Infection Due to Central Venous Catheter, Bloodstream Infection Due to Hickman Catheter
Interventions
Ethanol, Heparin Lock, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Jul 21, 2026, 11:09 PM EDT
Completed Not applicable Interventional Results available

Safe Critical Care: Testing Improvement Strategies

NCT00975923
View directory record Official record
Conditions
Central Line-associated Bloodstream Infection (CLABSI), Ventilator Associated Pneumonia
Interventions
Collaborative Group, Tool Kit
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
1 Year and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Jul 21, 2026, 11:09 PM EDT
Completed No phase listed Observational

Dental Study in Cancer Patients With Central Venous Catheters

NCT00798330
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Rajesh Lalla
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Jul 21, 2026, 11:09 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

NCT06749457
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
AZD7760, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
42
States / cities
Huntsville, Alabama • Chula Vista, California • Glendale, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 21, 2026, 11:09 PM EDT